ClinicalTrials.Veeva

Menu

Navi-Star Thermo-Cool Catheter For Ablation of Atrial Fibrillation

University of Oklahoma (OU) logo

University of Oklahoma (OU)

Status

Completed

Conditions

Paroxysmal Atrial Fibrillation

Treatments

Device: GP ablation + PV isolation

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The objective of this study is to demonstrate that the NAVI-STAR THERMO-COOL catheter can be used to safely and effectively reduce symptomatic episodes of paroxysmal atrial fibrillation in patients with frequent (>3 episodes/month) or infrequent <3 episodes/month)atrial fibrillation resistant to at least one Class I or Class III antiarrhythmic drug.

Full description

The ability of a saline irrigated catheter to deliver RF energy at higher power with a lower electrode-tissue interface temperature, combined with the anatomical guidance of electroanatomical mapping should allow:

  1. Isolation of the pulmonary veins at the LA-PV junction with the same or lower risk of pulmonary vein stenosis;
  2. Creation of continuous, transmural linear left atrial lesions with the same or lower risk of thromboembolism;
  3. These two factors will eliminate documented episodes of symptomatic sustained AF in patients with frequent (>3 episodes/month) or infrequent (<3 episodes/month);
  4. Patients with interruption of the vagal response (sinus bradycardia or AV block) during stimulation at the sites of left atrial autonomic ganglionated plexi (GP) will have lower recurrence of atrial fibrillation.

Enrollment

119 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age greater or equal to 18 years
  2. At least one documented episode of atrial fibrillation (AF) within the previous 6 months.
  3. Failure of at least one antiarrhythmic drug (Class I or III) defined as recurrence of AF or adverse effect.
  4. Informed consent obtained.

Exclusion criteria

  1. Left atrial thrombus
  2. Acute myocardial infarction within eight (8) weeks
  3. Atriotomy within eight (8) weeks
  4. Decompensated heart failure (unless the AF is thought to be a significant etiologic factor and AF ablation is clinically indicated)
  5. Pregnancy
  6. Ablation in a pulmonary vein within 4 months.
  7. Occurrence of perforation during an ablation procedure performed less than two months prior to the planned ablation date.
  8. Significant congenital anomaly or medical problem that, in the opinion of the investigator, would preclude enrollment in the study.
  9. Enrolled in an investigational study evaluating another device or drug
  10. Unwilling to participate in the study or unavailable for follow-up visits.
  11. Incarcerated

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

119 participants in 1 patient group

GP + PVI ablation
Active Comparator group
Description:
This study contains only one arm, which is GP ablation + PV antrum isolation. The intervention (GP ablation + PV isolation) was performed using ThermoCool Navistar catheters in all patients
Treatment:
Device: GP ablation + PV isolation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems